CClinicalTrials.gg
RecruitingNCT05227391Updated Jun 22, 2023

Live Birth After Letrozole-stimulated Cycles Versus Hormone Replacement Treatment Cycles for the First Frozen Embryo Transfer in Women With PCOS

An interventional study of Oral Letrozole and Oral estradiol valerate in PCOS, sponsored by Reproductive & Genetic Hospital of CITIC-Xiangya. Recruiting at 1 site in China. Open to female participants aged 20 Years to 38 Years. Per ClinicalTrials.gov, last updated 2023-06-22.

Sponsored by Reproductive & Genetic Hospital of CITIC-Xiangya · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
1,078
Allocation
Randomized
Ages
20 Years to 38 Years
Sex
Female
01

Study summary

This is a multicenter randomized controlled trial comparing the efficacy and safety of two endometrial preparation protocols for the first frozen embryo transfer cycle in PCOS with whole embryo freezing. Subjects will be randomized to letrozole-stimulated group or hormone replacement treatment group in their first frozen embryo transfer cycle, and their pregnancy and perinatal outcomes during this cycle will be followed up and analysis.

02

Conditions studied

  • PCOS
03

Who can participate

Ages eligible
20 Years to 38 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

    1. women diagnosed with PCOS according to modified Rotterdam criteria;
    1. Women who are participating in their first cycle of IVF or ICSI.
    1. Women whose IVF/ICSI ovarian stimulation protocol was either GnRH antagonist protocol or long agonist protocol.
    1. Women with whole embryos freezing.
    1. Women aged 20 to 38 years old;
    1. Women BMI 18 kg/m2 to 30 kg/m2
    1. Women with at least one good-quality embryo suitable for transfer, including day 3 cleavage stage embryo with grade 7CI /8CI and day 5 or day 6 blastocyst with grade 4BB or higher.

Exclusion criteria

Exclusion Criteria:

    1. Women who has a history of recurrent spontaneous abortion.
    1. Women with unilateral/bilateral oophorectomy.
    1. Women with untreated Hydrosalpinx.
    1. Women with a uterine cavity abnormality, such as a uterine congenital malformation, untreated uterine septum (except shallow uterine septum), adenomyosis, submucous myoma, or moderate to severe intrauterine adhesions.
    1. Women with uncontrolled diabetes mellitus, thyroid disease and hypertension.
    1. Women who are indicated and planned to undergo preimplantation genetic test (PGT).
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,078 participants (estimated)

Study arms

  • Experimental
    Letrozole-stimulated group

    Procedure: Oral Letrozole

  • Active comparator
    Hormone replacement treatment group

    Procedure: Oral estradiol valerate

Interventions

  • ProcedureOral Letrozole

    Oral Letrozole at a dose of 2.5mg daily will be started on days 3-5 of the menstrual cycle and will be continued for 5 days.

  • ProcedureOral estradiol valerate

    Oral estradiol valerate at a dose of 3mg twice daily will be started on days 3-5 of the menstrual cycle.

05

What researchers measure

Primary outcomes

  1. Live birth rate

    Number of women with live birth/ number of women randomized to the specific group. Live birth is defined as the delivery of any viable infant at 28 weeks or more of gestation.

    Time frame: 11 months

Secondary outcomes

  1. Clinical pregnancy rate

    Number of women with clinical pregnancy /number of women randomized to the specific group. Clinical pregnancy was defined as the presence of at least one gestational sac in the uterine cavity on ultrasound at about 28 days after embryo transfer.

    Time frame: 2 months

  2. Biochemical pregnancy rate

    Number of women with biochemical pregnancy /number of women randomized to the specific group. Biochemical pregnancy was defined as a human chorionic gonadotropin level of more than 10 milli-International unit (mIU) per milliliter (ml) as measured at about 14 days after embryo transfer.

    Time frame: 1.5 months

  3. Miscarriage rate

    Number of women with miscarrage / number of women with clinical pregnancy. Miscarriage refers to a complete spontaneous abortion or a nonviable pregnancy before 28 weeks of gestation.

    Time frame: 9 months

  4. Cycle cancellation rate

    Number of women who initiated endometrial preparation without embryos transfer / number of women randomized to the specific group.

    Time frame: 1 month

  5. Birth weight

    Weight of newborns at delivery.

    Time frame: 11 months

  6. Incidence of obstetric and perinatal complications

    Number of pregnancies with complications / number of clinical pregnancies.

    Time frame: 11 months

  7. Incidence of neonatal complications

    Number of live births with neonatal complications / number of live births.

    Time frame: 11 months

  8. Ectopic pregnancy rate

    Number of women with ectopic pregnancy /number of women randomized to the specific group. Ectopic pregnancy will be defined as implantation outside the uterine cavity, as confirmed by sonography or laparoscopy.

    Time frame: 2 months

06

Study locations

1 of 1 sites recruiting
  • Reproductive & Genetic Hospital of CITIC-Xiangya
    Changsha, Hunan 410000, China
    • Yuan Li, doctor · Contact · 1002251255@qq.com · +86-731-84566688
    • Fei Gong, PhD · Principal investigator
    Recruiting
07

References and documents

Individual participant data

Plan to share: Yes — All the individual participant data collected during the trial will be shared after deidentification upon request. Study protocol, Statistical analysis plan, informed consent forms, and clinical study report will be available upon request. Data will be available from 3 months following first publication and ending 5 years after the study has been concluded. Individual participant data will be shared with researches who provide a methodologically sound proposal and whose proposed use of the data has been approved by an independent review committee.

Supporting information: Study protocol, Sap, Icf, Csr, Analytic code

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05227391
Lead sponsor
Reproductive & Genetic Hospital of CITIC-Xiangya
Responsible party
Sponsor
First posted
Feb 7, 2022
Start date
Mar 16, 2022
Primary completion
Jun 30, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Jun 22, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion